MedTrace Logo

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

NCT04575558 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-05

No results posted yet for this study

Summary

Multicenter, double blind, randomized clinical trial for high-risk patients over 18 years of age, symptomatic for COVID-19 infection, without any severity criteria

Conditions

  • Sars-CoV2

Interventions

DRUG

Hydroxychloroquine and Azithromycin

Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD

Sponsors & Collaborators

  • Oncoclínicas

    collaborator INDUSTRY

  • Latin American Cooperative Oncology Group

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2020-09-01
Completion
2020-10-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575558 on ClinicalTrials.gov